MichaÃ«l Duruisseaux

List of Publications by Year
in descending order

45 papers	1,919 citations	279487 23 h-index	264894 42 g-index
52 all docs	52 docs citations	52 times ranked	3137 citing authors

#	Article	IF	Citations
1	Lung cancer epigenetics: From knowledge to applications. Seminars in Cancer Biology, 2018, 51, 116-128.	4.3	202
2	Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2016, 34, 4079-4085.	0.8	171
3	Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. Lancet Respiratory Medicine,the, 2018, 6, 771-781.	5.2	167
4	Efficacy of First-Line Chemotherapy in Patients with Advanced Lung Sarcomatoid Carcinoma. Journal of Thoracic Oncology, 2013, 8, 1574-1577.	0.5	165
5	Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study. Oncotarget, 2017, 8, 21903-21917.	0.8	140
6	Pulmonary Fibrosis in Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis. Medicine (United States), 2014, 93, 340-349.	0.4	122
7	Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages. Lung Cancer, 2016, 98, 51-58.	0.9	110
8	Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas. Human Pathology, 2016, 52, 9-18.	1.1	80
9	Blood vessel invasion is a major feature and a factor of poor prognosis in sarcomatoid carcinoma of the lung. Lung Cancer, 2014, 85, 276-281.	0.9	62
10	Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting. European Journal of Cancer, 2019, 121, 192-201.	1.3	51
11	ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer. Lung Cancer, 2018, 116, 15-24.	0.9	44
12	Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors. European Journal of Cancer, 2020, 132, 61-70.	1.3	42
13	How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?. Frontiers in Immunology, 2020, 11, 492.	2.2	40
14	Prognostic Impact of Paraneoplastic Cushingâ€™s Syndrome in Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2014, 9, 497-505.	0.5	34
15	Clinicopathologic Features and Response to Therapy ofNRG1Fusionâ€“Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. Journal of Clinical Oncology, 2021, 39, 2791-2802.	0.8	32
16	Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy. Lung Cancer, 2013, 79, 167-172.	0.9	31
17	NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma. Cancer Medicine, 2016, 5, 3579-3585.	1.3	31
18	Therapeutic Potential of Afatinib inNRG1Fusion-Driven Solid Tumors: A Case Series. Oncologist, 2021, 26, 7-16.	1.9	31

#	Article	IF	Citations
19	VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations. MAbs, 2014, 6, 1638-1648.	2.6	30
20	Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units. Intensive Care Medicine, 2015, 41, 164-165.	3.9	28
21	Lepidic predominant adenocarcinoma and invasive mucinous adenocarcinoma of the lung exhibit specific mucin expression in relation with oncogenic drivers. Lung Cancer, 2017, 109, 92-100.	0.9	28
22	Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110196.	1.4	27
23	Selection criteria for intensive care unit referral of lung cancer patients: a pilot study. European Respiratory Journal, 2015, 45, 491-500.	3.1	26
24	The impact of intracytoplasmic mucin in lung adenocarcinoma with pneumonic radiological presentation. Lung Cancer, 2014, 83, 334-340.	0.9	25
25	Lorlatinib for advanced anaplastic lymphoma kinaseâ€“positive nonâ€“small cell lung cancer: Results of the IFCT-1803 LORLATU cohort. European Journal of Cancer, 2022, 166, 51-59.	1.3	14
26	Pro-tumoural CXCL10/CXCR3-A autocrine loop in invasive mucinous lung adenocarcinoma. ERJ Open Research, 2017, 3, 00047-2016.	1.1	13
27	Lung cancer surgical treatment after solid organ transplantation: A single center 30-year experience. Lung Cancer, 2020, 139, 55-59.	0.9	13
28	Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients. Cancers, 2021, 13, 1040.	1.7	13
29	Are ALK rearrangement variants promising predictive biomarker of ALK tyrosine kinase inhibitors efficacy?. Annals of Oncology, 2017, 28, 1401.	0.6	12
30	Major and prolonged response to pemetrexed in two cases of lung adenocarcinoma with bronchioloalveolar carcinoma features. Lung Cancer, 2009, 65, 385-387.	0.9	11
31	Influenza vaccination in patients with haematologic malignancies: analysis of practices in 200 patients in a single center. Bulletin Du Cancer, 2010, 97, E33-E36.	0.6	9
32	Chemotherapy Effectiveness After First-Line Gefitinib Treatment for Advanced Lepidic Predominant Adenocarcinoma (Formerly Advanced Bronchioloalveolar Carcinoma): Exploratory Analysis of the IFCT-0401 Trial. Journal of Thoracic Oncology, 2012, 7, 1423-1431.	0.5	9
33	Operation and Chemotherapy: PrognosticÂFactors for Lung Cancer WithÂOneÂSynchronous Metastasis. Annals of Thoracic Surgery, 2018, 105, 957-965.	0.7	9
34	Lorlatinib: a new treatment option for ROS1-positive lung cancer. Lancet Oncology, The, 2019, 20, 1622-1623.	5.1	9
35	The Role of Pemetrexed in Lung Adenocarcinoma, Mixed Subtype with Bronchioloalveolar Carcinoma Features. Current Drug Targets, 2010, 11, 74-77.	1.0	8
36	Is there a specific phenotype associated with the different subtypes of KRAS mutations in patients with advanced non-small-cell lung cancers?. Lung Cancer, 2015, 90, 561-567.	0.9	8

#	Article	IF	Citations
37	Factors associated with early progression of nonâ€smallâ€cell lung cancer treated by epidermal growth factor receptor tyrosineâ€kinase inhibitors. Cancer Medicine, 2014, 3, 61-69.	1.3	6
38	A Rare Fusion of CLIP1 and ALK in a Case of Nonâ€“Small-Cell Lung Cancer With Neuroendocrine Features. Clinical Lung Cancer, 2019, 20, e535-e540.	1.1	4
39	Carcinome sarcomatoÃ¯de pulmonaire : un modÃ¨le de rÃ©sistance aux sels de platine. Revue Des Maladies Respiratoires Actualites, 2012, 4, 673-677.	0.0	2
40	A reply to â€œA comment on â€œLung cancer surgical treatment after solid organ transplantation: a single center 30-year experienceâ€. Lung Cancer, 2020, 145, 222-224.	0.9	2
41	CD74-NRG1 : un nouveau gÃ¨ne de fusion dans les adÃ©nocarcinomes pulmonaires caractÃ©risant les adÃ©nocarcinomes mucineux invasifs. Bulletin Du Cancer, 2014, 101, 529-530.	0.6	1
42	Pathologie avancÃ©e et dÃ©faillances dâ€™organesÂ: outil dâ€™aide Ã la dÃ©cision. Medecine Palliative, 2014, 13, 150-154.	0.0	1
43	Itâ€™s far better to be alone than to be in bad company. Journal of Thoracic Disease, 2019, 11, 649-651.	0.6	1
44	Calpain 1 in bronchoalveolar lavage fluid is associated with poor prognosis in lepidic predominant pulmonary adenocarcinoma. Bulletin Du Cancer, 2019, 106, 179-188.	0.6	1
45	Are all ALK rearrangements created equal?. Translational Cancer Research, 2017, 6, S270-S275.	0.4	1